| Description |
1 online resource |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
Cancer etiology, diagnosis, and treatments |
|
Dermatology--laboratory and clinical research |
|
Dermatology--laboratory and clinical research series.
|
|
Cancer etiology, diagnosis, and treatments.
|
| Bibliography |
Includes bibliographical references and index. |
| Contents |
MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS -- MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter 1: Melanoma Progression to Metastatic Disease: The Role of the PI3K/AKT and Wnt/β-Catenin Pathways -- Abstract -- 1. PI3K/AKT Signaling Pathway and Its Components -- 1.1. Overview -- 1.2. Components of the PI3K Pathway -- 1.2.1. PI3K Isoforms -- 1.2.2. Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) -- 1.2.3. AKT |
|
1.3. PI3K Pathway Activation and Downstream Targets1.4. PI3K in Cancer -- 2. PI3K Pathway in Melanoma -- 2.1. Melanoma -- 2.1.1. Overview -- 2.1.2. Stages of Melanoma -- 2.1.3. Melanoma and Common Mutations of Signaling Pathways -- 2.2. PI3K and Melanoma Progression -- 3. PI3K Mediated Crosstalk in Melanoma Progression -- 3.1. PI3K â€? MAPK Crosstalk -- ERK 1/2 Module -- JNK Module -- 3.2. PI3K â€? NF-ÎðB Cross Talk -- 3.3. PI3K â€? TGFβ Pathway Crosstalk -- 3.4. PI3K â€? Notch Pathway Crosstalk -- 3.5. PI3K â€? JAK-STAT Pathway Crosstalk |
|
3.6. PI3K- mTOR Crosstalk4. Wnt/β-Catenin and PI3K Pathway -- 4.1. β-Catenin -- 4.1.1. Structure and Function -- At Cellular Membrane -- In the Cytoplasm and Nucleus -- 4.1.2. β-Catenin/Canonical Wnt Pathway -- 4.1.3. Active β-Catenin -- 4.1.4. Localization -- 4.1.5. β-Catenin in Cancer -- 4.1.6. β-Catenin in Melanoma -- 4.2. Crosstalk between the PI3K and Canonical Wnt Pathways in Melanoma Progression -- 4.2.1. GSK3β As a Potential Candidate to Mediate Crosstalk between Wnt/β-Catenin and PI3K Pathways |
|
4.2.2. Other Potential Candidates That Mediate Crosstalk between Wnt/β-Catenin and PI3K Pathways4.2.2.1. AKT -- 4.2.2.2. PI3K -- 4.2.2.3. mTOR -- 4.2.2.4. TGFβ1 -- Current Therapeutics of Melanoma and Concluding Remarks -- References -- Chapter 2: Cutaneous Melanoma: Molecular Biology, Risk Factors and Treatment Options -- Abstract -- 1. The Biology of Cutaneous Melanoma -- 1.1. Risk Factors -- 1.2. Development of Cutaneous Melanoma -- 1.2.1. Models for heterogeneity in Cutaneous Melanoma |
|
1.2.2. Pathways Involved in Cutaneous Melanoma Development and ProgressionCell Proliferation and Angiogenesis Pathways -- Pigment Synthesis Pathways -- 1.3. Cutaneous Melanoma and the Immune System -- The theory of Cancer Immunoediting -- Evidences of immunoediting in Cutaneous Melanoma -- 2. Cutaneous Melanoma Treatment and Management -- 2.1. Targeted Therapies -- 2.2. Immunotherapy -- 2.2.1. Therapeutic Vaccines -- 2.2.2. Our Experience with Therapeutic Vaccines -- Therapeutic Vaccines of Irradiated Allogeneic Cutaneous Melanoma Cells |
| Summary |
Melanoma accounts for only 4% of all skin cancer cases but most of skin cancer-related death. The rising incidence of melanoma makes this tumor an important public health problem. In this book, the authors present current research in the study of the molecular biology, risk factors and treatment options for melanoma. Topics include the role of P13K/AKT and Wnt/Ý-Catenin pathways in melanoma's progression to metastatic disease; cutaneous melanoma; molecular determinants of melanoma vasculogenic mimicry; new aspects of the molecular biology of melanoma metastasis; the surgical extent of regional. |
| Subject |
Melanoma.
|
|
Melanoma -- Treatment.
|
|
Melanoma |
|
Melanoma -- therapy |
|
Mélanome.
|
|
Mélanome -- Traitement.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Melanoma
|
|
Melanoma -- Treatment
|
| Added Author |
Jones, Alexander C., editor.
|
| Other Form: |
Print version: Melanoma. New York : Nova Biomedical, ©2013 9781628086089 (DLC) 2013945019 |
| ISBN |
9781628086119 (ebook) |
|
1628086114 |
|
1628086084 |
|
9781628086089 |
| Standard No. |
DEBBG BV041572359 |
|
NZ1 15198307 |
|
